Evidence map›Paper›PMID 10337023›Full record

ArticleClinical and experimental immunology1999

Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery.

A E Sousa, A F Chaves, M Doroana, F Antunes, R M Victorino

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2010
    Review
  5. Review
  6. Article
  7. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals.Proceedings of the National Academy of Sciences of the United States of America · 2003
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

A E SousaCellular Immunology Unit, Centre for Biology and Molecular Pathology, Faculty of Medicine of Lisbon, Portugal.
A F Chaves
M Doroana
F Antunes
R M Victorino
Hospital de Santa Maria · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fas, CD40L and OX40 are members of the tumour necrosis factor (TNF) receptor superfamily with critical roles in T cell activation and death, B cell function, dendritic cell maturation and leucocyte traffic regulation. The aim of this study was to evaluate the effects of anti-retroviral therapy (HAART) on CD40L, OX40 and Fas expression on freshly isolated peripheral blood T cells by three-colour flow cytometry and compare them with lymphoproliferative responses, peripheral blood cell counts and viral load. Fourteen asymptomatic HIV-1+ patients treated with Lamivudine, Stavudine and Nelfinavir were prospectively investigated sequentially for 48 weeks. At baseline, patients exhibited significantly enhanced proportions and counts of CD40L+ and OX40+ cells within the CD4 subset which were corrected by weeks 8-16 of HAART. Interestingly, in the five patients showing viral load rebound during therapy in spite of increasing CD4 counts, the reduction of the levels of these costimulatory molecules was similarly maintained. Therapy induced a decrease in the over-expression of Fas, particularly in the CD4 subset where normal levels were reached at week 8. This reduction occurred in parallel with the major recovery of lymphoproliferative responses. Higher basal levels and lower reduction of Fas were associated with suboptimal suppression of viraemia. In conclusion, this previously undescribed increased expression of CD40L and OX40 may play a role in the HIV-associated pan-immune activation and represent a possible target for immunointervention, as suggested for several immunologically mediated diseases. Moreover, HAART induced an early correction of the over-expression of Fas, CD40L and OX40 in CD4 T cells which could be involved in the recovery of the cell traffic disturbances and in the T cell renewal capacity.

Indexed as

HIV-1Receptors, Tumor Necrosis FactorAcquired Immunodeficiency SyndromeAdultAnti-HIV AgentsCD40 LigandCD4 Lymphocyte CountCell MovementDrug Therapy, Combinationfas ReceptorFemaleHumansLymphocyte ActivationMaleMembrane GlycoproteinsMiddle AgedAnti-HIV AgentsCD40 Ligandfas ReceptorMembrane GlycoproteinsReceptors, OX40Receptors, Tumor Necrosis FactorTNFRSF4 protein, humanTumor Necrosis Factor Receptor Superfamily, Member 7

Identifiers

PMID10337023
PMCPMC1905269
OpenAlexW2051159484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.